Vav1: A Key Player in Agonist-Induced Differentiation of Promyelocytes from Acute Myeloid Leukemia (APL) by Valeria Bertagnolo et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Vav1: A Key Player in Agonist-Induced 
Differentiation of Promyelocytes from  
Acute Myeloid Leukemia (APL) 
Valeria Bertagnolo, Federica Brugnoli and Silvano Capitani 
University of Ferrara, Section of Human Anatomy,  
Department of Morphology and Embryology,  
Italy 
1. Introduction  
Acute promyelocytic leukemia (APL) is the M3 subtype of acute myeloid leukemia (AML), 
characterized by aberrant hyperproliferation of progenitors originally committed to 
terminal differentiation into granulocytes but blocked at the promyelocytic stage. Although 
clinical studies have introduced treatments employing arsenic trioxide, anthracyclines and 
anti-CD33 monoclonal antibodies, all-trans retinoic acid (ATRA)-based therapy represents, 
until today, the standard cure of APL patients (Lo-Coco & Ammatuna, 2006; Tallman, 2007). 
ATRA treatment of APL constitutes, at present, the only example of successful 
differentiation therapy of a human cancer, in which tumor cells are induced to complete 
their maturation to neutrophils. Studies on both APL blasts and APL-derived cell lines have 
elucidated that ATRA acts throughout a complex network that includes the degradation of 
the PML/RAR fusion protein and the activation of RAR-mediated gene transcription 
(Breitman et al., 1980; Lanotte et al., 1991; Yang et al., 2003). In addition, it has been reported 
that ATRA- and phorbol 12-myristate 13-acetate (PMA)-mediated differentiation of human 
myeloid leukemia cell lines results in changes of their sensitivity to chemotherapeutic drugs, 
suggesting that advantages in the cure of APL and other malignancies could be obtained by 
combining differentiating agents and conventional anticancer drugs (Jasek et al., 2008; 
Kogan, 2009; Nasr et al., 2008).   
Even if the mechanism by which ATRA interacts with its receptor located on specific DNA 
sequences is well known, the events mediated by the ATRA target genes, able to elicit the 
integrated signaling networks that promote maturation of tumoral promyelocytes, have not  
been fully clarified and are currently under study to also identify specific molecular targets 
for new therapies of APL.  
One of the proteins up-regulated by ATRA in APL-derived cells and that resulted chiefly 
involved in the maturation program of tumoral promyelocytes is Vav1, the sole member of 
the Vav family of proteins physiologically expressed only in haematopoietic cells, where it 
works as an important signal transducer in immune response (Katzav, 2009; Tybulewicz, 
2005). Relevant insights into the function of Vav1 in hematopoietic cells have been provided 
by studies with knockout mice, demonstrating that the targeted down-modulation of Vav1 
compromises maturation of both lymphoid and myeloid cells (Zhang et al., 1994). In 
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particular, a severe impairment of IL-2 production and calcium mobilization in response to 
external stimuli has been found in T and B cells (Fujikawa et al., 2003; Haubert & 
Weckbecker, 2010) and the defective motility observed in the Vav1-/- neutrophils, 
concomitant with the decrease in migration, has been demonstrated to reduce the capacity 
for an innate immune response (Phillipson et al., 2009). Vav1 has a critical role also in 
regulating the acquisition by macrophages of maturation-related competence, as 
demonstrated by the smaller adhesive area, the reduced motility and the lower migration 
speed of macrophages from Vav1-deficient mice (Hall et al., 2006; Wells et al., 2005). More 
recently, Vav1 activity has been demonstrated to be required specifically for SDF1α-
dependent perivascular homing and subsequent engraftment of hematopoietic stem cells 
(Sanchez-Aguilera et al., 2011). In both lymphoid and myeloid cells, Vav1 is involved in the 
dynamic regulation of the filamentous actin cytoskeleton, critical to numerous physical 
cellular processes, including adhesion, migration and phagocytosis (Cougoule et al., 2006; 
Stricker et al., 2010).  
Vav1 contains an array of structural motifs that enable it to play a role in several distinct cell 
functions, like cytoskeletal reorganization and regulation of gene expression during 
proliferation, maturation, and apoptosis of hematopoietic cells (Clevenger et al., 1995; 
Fischer et al., 1998; Kong et al., 1998). The Vav1 domains include a DH region which exhibits 
a GDP/GTP exchange activity for the RhoA, Rac1 and CDC42 small GTPases, a PH domain 
interacting with phosphoinositides, two SH3 domains and one SH2 domain mediating 
protein-protein interactions, a CH domain that functions as an actin-binding motif and an 
AC region that contains 3 regulatory tyrosines. Vav1 also possesses 2 putative nuclear 
localization signals, indicative for a role of the protein also inside the nuclear compartment 
(Bustelo, 2001).  
In both myeloid and lymphoid cells, the best known function of Vav proteins is the 
guanosine exchange factor (GEF) for small G proteins which is modulated, at variance with 
the other exchange factors for Rho/Rac in humans, by phosphorylation on tyrosine residues 
(Bustelo, 2002). However, some functions of Vav1 in hematopoietic cells are independent of 
its GEF activity and are attributed to its ability to interact with a number of signalling 
molecules, in both cytoplasm and nucleus. In particular, inside the nuclear compartment 
Vav1 seems to play its most intriguing role as part of transcriptionally active complexes 
(Houlard et al., 2002) and by interacting with components of the DNA-dependent protein 
kinase complex as well as with hnRNP proteins (Romero et al., 1996, 1998). 
In addition to the role played in the acquisition of a mature phenotype by normal 
hematopoietic cells, Vav1 has been found to promote the agonist-induced completion of the 
differentiation program of tumoral myeloid precursors. In cell lines  derived from APL patiens 
treated with differentiating agents Vav1 plays indeed multiple roles aimed to regulate 
different aspects of maturation along the neutrophilic and the monocytic/macrophagic 
lineages. Since Vav1 may be recruited by various differentiating agents and plays a central role 
in the completion of the differentiation program of leukemic promyelocytes along diverse 
hematopoietic lineages, it might be considered a common target for developing new 
therapeutic strategies for the different subtypes of myeloid leukemias.  
2. Vav1 and netrophil-like phenotypical maturation    
Promyelocytes derived from APL, which are blocked at different steps of their neutrophil 
differentiation, contain levels of Vav1 variably lower than those found in mature 
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neutrophils. Treatments with differentiating doses of ATRA induce a significant increase of 
Vav1 expression in primary blasts obtained from the bone marrow of APL patients as well 
as in the APL-derived cell lines HL-60 and NB4. A similar increase of Vav1 is observed 
when normal CD34+ hematopoietic progenitors are treated with a cytokine cocktail 
promoting granulocytic differentiation, clearly indicating that an adequate expression of 
Vav1 has to be achieved along with neutrophil maturation of both normal precursors and 
poorly differentiated neoplastic cells (Bertagnolo et al., 2005). These evidence, obtained in a 
variety of normal and neoplastic  cells under different experimental conditions, ascribe to 
Vav1 the potential role of a ubiquitous key player in the path leading myeloid precursors to 
acquire the mature phenotype of differentiated neutrophils.  
The issue of whether the increase of Vav1 observed in differentiation of tumoral 
promyelocytes is merely designed to the function of the protein in mature cells or, more 
intriguingly, it is functionally relevant to the maturation mechanism, has been addressed by 
studies in which the expression of Vav1 was forcedly modulated. The experiments have 
been performed in ATRA treated HL-60 and NB4 cells, which are blocked at different levels 
of granulocytic differentiation, and thus constitute models well suited to better understand 
the role of Vav1 in the maturation process. As a consequence of Vav1 over-expression 
during ATRA treatment of both cell lines, the expression of the myeloid surface marker 
CD11b increases, indicating that Vav1 supports the role of ATRA in regulating the 
maturation process. On the other hand, the sole over-expression of Vav1 is capable to 
significantly induce the expression of CD11b only in HL-60 cells, that, compared to NB4 
cells, are blocked to a less differentiated stage (Bertagnolo et al., 2005). This suggests the 
existence of a direct and ATRA-independent role of Vav1 in regulating the expression of 
CD11b, at least in cells that are blocked at early stages of the neutrophilic maturation.   
Neutrophils radically change in shape during development and functional life (Sanchez & 
Wangh, 1999). Accordingly, profound rearrangements of the cell morphology take place 
throughout differentiation of myeloid precursors along the granulocytic lineage, and the 
nucleus is the cell compartment that undergoes the biggest architectural changes by a 
mechanism still largely unknown. Modifications of the nuclear shape constitute one of the 
markers of neutrophil maturation of tumoral promyelocytes and are particularly evident 
after treatment with ATRA of HL-60 cells, according to the notion that this cell type is 
blocked at an early stage of maturation. On the other hand, the sole over-expression of Vav1 
is unable to induce nuclear modifications in both HL-60 and NB4 cells, indicating that other 
ATRA-induced events are required to regulate the maturation-related rearrangements of cell 
morphology (Bertagnolo et al, 2005).  
The use of siRNAs specific for Vav1 unequivocally demonstrates that Vav1 is not 
dispensable for the progression of tumoral promyelocytes along the granulocytic lineage. In 
fact, the down-modulation of Vav1 expression during ATRA treatment of both HL-60 and 
NB4 cells counteracts the agonist-induced increase of CD11b expression and prevents  the 
maturation-related modifications of cell/nucleus morphology, definitely assigning to Vav1 
a crucial role in regulating phenotypical maturation of APL-derived cells (Bertagnolo et al, 
2005, 2008).    
2.1 Tyrosine phosphorylation of Vav1  
In parallel with the increase of Vav1 expression, ATRA treatment of HL-60 and NB4 cells 
also induces Vav1 tyrosine phosphorylation. Since, in the whole cell, the rise of the 
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phosphosphorylation level is almost proportional to the increase in total Vav1 amount, 
ATRA seems to ensure to differentiating cells the achievement of an adequate amount of 
tyrosine phosphorylated Vav1, according with the functions of Vav1 in mature neutrophils. 
On the other hand, the accumulation of tyrosine-phosphorylated Vav1 inside the nuclear 
compartment seems to be a distinctive feature of the differentiation process induced by 
ATRA in APL-derived cells (Bertagnolo et al., 2005). In fact, a progressive increase of 
tyrosine phosphorylated Vav1 inside the nucleus accompanies the agonist-induced 
maturation (Bertagnolo et al., 1998), indicative of a specific role of tyrosine phosphorylated 
Vav1 inside the nuclear compartment. The tyrosine phosphorylation level of nuclear Vav1 
reaches a maximum in ATRA-treated NB4 cells, which constitute the cell model with the 
most advanced level of neutrophil maturation among APL-derived precursors (Bertagnolo 
et al., 2005), clearly correlating tyrosine phosphorylated Vav1 with the maturation-related 
events that occur inside the nuclear compartment and opening the question of which 
kinase/s is/are involved in this process. 
In both myeloid and lymphoid cells, Vav1 is phosphorylated in tyrosine/s by receptors with 
intrinsic tyrosine kinase activity or by membrane and/or cytoplasmic tyrosine kinases of the 
Syk/Zap70, Src and Jak families (Bustelo, 2002). More recently, also the c-Abl kinase has 
been reported to be specifically involved in regulating the activity of Vav1 in integrin-
mediated neutrophil adhesion (Cui et al., 2009). Recruitment and phosphorylation of Vav1 
depend on its ability to interact with a number of signalling proteins by means of its various 
domains. In particular, the interaction between the SH2 domain of Vav1 and 
phosphorylated proteins is thought to serve for recruitment of activated kinases, which in 
turn can phosphorylate Vav1 (Bustelo, 2002). The Syk/ZAP-70 family of tyrosine kinases 
constitutes an example of proteins that contain two SH2 domains, a tandem sequence that 
might confer high specificity in tyrosine kinase- mediated signalling. In addition, both ZAP-
70 and Syk contain a consensus binding sequence for the Vav1 SH2 domain that seems to be 
critical for antigen receptor-mediated signal transduction (Ottinger et al., 1998). 
Experiments performed with HL-60 cells have demonstrated the association of tyrosine 
phosphorylated Syk with the Vav1-SH2 domain, in both whole cell and nuclear 
compartment, as a consequence of ATRA treatment (Bertagnolo et al., 2001). These data are 
in agreement with the notion that activation of Syk occurs in differentiating HL-60 cells (Qin 
& Yamamura, 1997) and mature neutrophils, in which it regulates migration (Schymeinsky 
et al., 2006) and the formation of lamellipodia during phagocytosis (Shi et al., 2006). While in 
whole HL-60 cells the Vav1/Syk association takes place regardless of their phosphorylation 
level and of ATRA treatment, the formation of Vav1/Syk complexes inside the nuclear 
compartment strongly increases during the differentiation process, suggesting a specific role 
for this tyrosine kinase in the nucleus. The role of Syk in phosphorylating Vav1 has been 
demonstrated by means of in vitro assays (Bertagnolo et al., 2001) and confirmed by the use 
of a pharmacological model of Syk inhibition, in which both HL-60 and NB4 cells were 
treated with Piceatannol (Bertagnolo et al., 2001, 2008), a tyrosine kinase inhibitor with a 
reported selectivity for Syk (Law et al, 1999; Seow et al., 2002).  
The Syk-dependent tyrosine phosphorylation of Vav1 during the ATRA-induced phenotypical 
differentiation is not relevant for the expression of the surface marker CD11b, as indicated by 
the use of Piceatannol in both HL-60 and NB4 cells, but seems to play a crucial role in 
regulating the reorganization of cell architecture.  In fact, when Piceatannol is administered in 
combination with ATRA, the modifications of nuclear morphology typical of granulocytic 
differentiation are almost completely abrogated, similarly to what observed when the 
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expression of Vav1 is down-modulated during the differentiation treatment (Bertagnolo et al., 
2008). However, since Piceatannol fails to abrogate completely the ATRA-induced tyrosine 
phosphorylation of Vav1 in both HL-60 and NB4 cells (Bertagnolo et al., 2008), other kinase/s, 
in addition to Syk, are probably recruited by ATRA in these cell models.  
The results from these inhibition studies support the hypothesized action model that 
requires tyrosine phosphorylated Vav1 in maturation of tumoral myeloid precursors. 
Nevertheless, the issue needs further investigations, in order to identify the kinase/s 
involved. In fact, by extending the analysis to other tyrosine kinase inhibitors, it has been 
found that PP1 and AG490, inhibitors of Src and Jak tyrosine kinase families, respectively, 
did not affect to any significant extent the tyrosine phosphorylation of Vav1 (Bertagnolo et 
al., 2004), leaving open the question of which other tyrosine kinases, in addition to Syk, 
phosphorylate Vav1 during maturation of tumoral promyelocytes.  
2.1.1 Participation to protein complexes with signaling molecules  
In addition to the obvious interaction with tyrosine kinases, the optimal phosphorylation of 
Vav1 seems to require the association with adaptor molecules that facilitate the spatial 
proximity between Vav1 and the upstream kinases. These associations also depend on the 
tyrosine phosphorylation of the involved proteins and often require the engagement of either 
the SH3 or the SH2 domains of Vav1 as interacting motifs (Bustelo, 2002). In this context, SLP-
76, an adaptor protein predominantly expressed in T cells and myeloid cells and which is a 
substrate for ZAP-70 and Syk tyrosine kinases, has been reported to associate, via tyrosine-
phosphorylated residues in its NH2-terminal domain, with the SH2 domain of Vav1 after 
ligation of the T-cell antigen receptor (Tuosto et al., 1996; Pauker & Barda-Saad,, 2011). SLP-76 
was also described as an important adaptor molecule that is regulated by Syk in C-reactive 
protein-stimulated platelets (Gross et. al, 1999) and that plays a critical role in FcRI-mediated 
activation of mast cells in vivo and in vitro (Pivniouk et al., 1999).  
Some of the Vav1-interacting molecules play a role in down modulation of Vav1 signals. A 
potential negative regulator of Vav1 is Cbl, which down-modulates Syk/ZAP-70 and other 
protein tyrosine kinases (Lupher et al., 1999). Cbl associates with Vav1 upon T-cell receptor 
stimulation of primary murine lymphocytes and Jurkat T cells. This interaction appears to 
require the whole SH3-SH2-SH3 COOH-terminal domain of Vav1 and a proline-rich 
sequence of Cbl and seems to inhibit the Vav1-dependent signal transduction (Bustelo et al., 
1997). Very recently, Chiang & Hodes (2011) have demonstrated a role of Cbl in repressing 
signaling events that can mediate thymic differentiation in the absence of Vav1, since Cbl 
inactivation rescued defective T cell development in Vav1-/- mice.  
The molecules involved in the recruitment and phosphorylation of Vav1 during the ATRA-
dependent granulocytic differentiation of tumoral promyelocytes were investigated in HL-
60 cells by using GST-fusion NH2-terminal and COOH-terminal Vav1-SH3 and GST-fusion 
Vav1-SH3-SH2-SH3 proteins. One of the proteins interacting with Vav1 in HL-60 cells is the 
adaptor molecule Cbl, present only in the cytoplasm and strongly phosphorylated in 
response to ATRA treatment. The Vav1/Cbl interaction in HL-60 cells occurs also in control 
conditions and requires the entire SH3-SH2-SH3 domain of Vav1 (Bertagnolo et al., 2001). 
The adaptor protein SLP-76 has been also identified as a phosphorylated protein interacting 
with the SH3-SH2-SH3 fragment of Vav1 in both cells and nuclei of HL-60 after ATRA 
treatment. Similarly to Cbl, SLP-76 associates with Vav1 also in control conditions, without 
quantitative changes due to the differentiation process. Vav1-associated SLP-76 was more 
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abundant in nuclei than in whole cell lysates, indicating a preferential association into the 
nucleus of these two molecules, in contrast with an exclusive cytoplasmic distribution of 
Vav1/Cbl complexes (Bertagnolo et al., 2001). 
The interaction of Vav1 with Cbl and SLP-76 in HL-60 cells may be correlated to the 
transmembrane signaling mediated by CD38, an early biomarker of ATRA-induced 
differentiation in the HL-60 cell line, in which it may play a causal role in myeloid 
differentiation (Lamkin et al., 2006). A correlation between Vav1 and CD38-activated 
signaling has been recently demonstrated by experiments in which the expression of a 
cytosolic deletion mutant of CD38 caused failure to up-regulate ATRA-induced proteins 
such as CD11b, Vav1 and Fgr, this latter able to phosphorylate Vav1 after ATRA treatment 
of HL-60 cells (Congleton et al., 2011).  
Exclusive of the ATRA treatment of HL-60 seems to be the compartmentalized association 
between Vav1 and interacting proteins during ATRA treatment, since Cbl/Vav1 complexes 
are located in the cytoplasm while SLP-76/Vav1 complexes reside in the inner nuclear 
compartment. This suggests that Vav1 is recruited by one or more signal transduction 
cascades, starting from cell membrane and directed to the nucleus and involving the two 
adaptor proteins Cbl and SLP-76, which may then discretely regulate the amount of Vav1 in 
the cytoplasmic and nuclear compartments (Fig. 1). 
The Vav1-associated protein complexes identified in HL-60 cells also contain the tyrosine 
kinase Syk. In particular, Vav1/Cbl/Syk complexes have been found in cytoplasm whereas 
Vav1/SLP-76/Syk complexes have been demonstrated inside the nuclear compartment. 
These associations are present in control conditions and result strongly increased after 
ATRA treatment (Bertagnolo et al., 2001). This suggests that, during the maturation of APL-
derived myeloid precursors, a sequence of signals originated from membrane receptors and 
directed to the nuclear compartment is ended to regulate the amount of tyrosine 
phosphorylated Vav1 inside the nucleus (Fig. 1) and that this pathway may involve the 
negative regulation of Cbl on Vav1 activity.  
In both cells and nuclei of HL-60 cells, other signalling molecules associate with Vav1 as a 
consequence of ATRA treatment. They include the 1 isoform of PI-PLC and the p85 
regulatory subunit of PI3K. In particular, ATRA treatment increases the binding of tyrosine-
phosphorylated Vav1 to both N-terminal and C-terminal SH2 domains of p85 (Bertagnolo et 
al., 1998). Since Vav1 is the only member of the Vav1/PLC-1/PI3K complex to possess a 
nuclear localization sequence (Bustelo, 2001), it is conceivable that Vav1 is directly involved 
in regulating the amount of PLC-1 and PI3K inside the nuclear compartment. 
2.1.2 Phosphorylation of Vav1 on Tyr745  
Vav1 contains 31 tyrosine residues whose phosphorylation was originally investigated 
almost exclusively in relation to the function of Vav1 as a GEF. A crucial role in this context 
seems to be played by Tyr174 in both lymphoid and myeloid cells, even if other mechanisms 
have emerged in the last few years as regulators of Vav1 GEF activity, and recent data 
suggest that Tyr174 is coversely involved in roles of Vav1 not mediated by GEF activity 
(Katzav, 2009).  In addition to Tyr174, other conserved residues, Tyr142 and Tyr160, have 
been described to be phosphorylated in activated Vav1. It has also been suggested that 
phosphorylation of the tyrosines located inside the acidic region of Vav1 may allow Tyr142, 
Tyr160, and Tyr174 to become docking sites for kinases, which can then phosphorylate 
additional tyrosine residues in Vav proteins (Miletic et al., 2006; Yu et al., 2010). Recently, 
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several of the tyrosine residues at the carboxyl terminus of Vav1 have been shown to be 
phosphorylated in cancer cells, raising the possibility that also these tyrosine residues play 
an important role in Vav1 function (Lazer et al., 2010).  
The residue Tyr174, phosphorylated by members of Syk/Zap70 and Src tyrosine kinase 
families, plays a central role in regulating GEF activity of Vav1 in mature  neutrophils, 
including 2 integrin-mediated neutrophil migration in vitro and neutrophil recruitment 
during the inflammatory response in vivo (Schymeinsky  et al., 2006). In APL-derived cells, 
ATRA induces the phosphorylation of Tyr174 in NB4 but not in HL-60 cells and 
independently of the activity of Syk (Bertagnolo et al., 2011). Both cytofluorimetrical analysis 
of CD11b expression and migration assays on NB4 cells over-expressing the Tyr174Phe-
mutated Vav1 have ruled out any relevant role for this tyrosine residue in supporting the 
activity of ATRA in this cell line (Bertagnolo et al., 2010). Since phosphorylation of Tyr174 in 
neutrophils has been mainly associated to the GEF activity of Vav1 in mature cells, these 
findings suggest that the ATRA-induced phosphorylation of Tyr174 occurs in parallel with 
differentiation and may constitute a marker of the acquisition of a mature phenotype. This 
hypothesis is confirmed by the failure of ATRA in inducing the phosphorylation of Tyr174 in 
HL-60 cells, that reach indeed only a partially differentiatiated phenotype (Bertagnolo et al., 
2011). 
Since the phosphorylation of Vav1 on the Tyr174 residue seems unrelated to the path by 
which tyrosine phosphorylated Vav1 affects the ATRA-induced maturation of APL-derived 
cells, proteomic studies have been undertaken to identify other tyrosine residues 
phosphorylated after ATRA treament in both HL-60 and NB4 cells. Mass spectra analysis 
performed on Vav1 immunoprecipitated from NB4 whole cells identified Tyr745 as an 
ATRA-induced phosphorylated residue, within a highly conserved Vav1 sequence. The 
analysis of maturation-related features in differentiating NB4 cells over-expressing the 
Tyr745Phe-mutated form of Vav1 have clearly shown that phosphorylation of this tyrosine 
residue is crucial in regulating CD11b expression as well as in promoting the acquisition of 
migratory capabilities (Bertagnolo et al., 2010). Even if Tyr745 has never been correlated 
with the known roles of Vav1, multiple sequence alignment analysis of proteins from 
different species indicates that this is a highly conserved aminoacid, likely involved in 
physiological roles of Vav1.   
Inhibition studies have ruled out the role of Syk in phosphorylating Tyr745 as a 
consequence of ATRA treatment and, at present, no data are available about the involved 
tyrosine kinase. This is in part due to the fact that analysis performed with softwares 
designed to predict cell signaling interactions using short sequence motifs failed to 
recognize the Tyr745 of Vav1 as a putative phosphorylation site by the known tyrosine 
kinases. However, some tyrosine residues of Vav1 are not surface exposed and/or may be 
involved in intramolecular interactions, thereby precluding their tyrosine phosphorylation 
and impairing their recognition by the data base analysis. Since Tyr745 is located inside a 
short helix on the SH2 domain of Vav1, its phosphorylation could be an event secondary to 
phosphorylation of other tyrosine residues, which may induce conformational changes of 
Vav1 allowing Tyr745 to become accessible to a specific tyrosine kinase.    
2.1.3 GEF activity  
The best known function of tyrosine phosphorylated Vav1 is a catalytic role as a GEF 
towards the Rho family of GTPases, in which Tyr174 is crucial. Tyr174 lies within an α-helix 
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and binds directly with the GTPase interaction pocket of the DH domain, blocking access to 
substrate and inhibiting Vav1 GEF activity. Phosphorylation releases Tyr174 from the 
binding pocket, relieving the auto-inhibition (Bustelo et al., 2001). The activity of the DH 
domain is also regulated by the CH domain, as deletion of this domain results in 
constitutively active GEF activity. It has been suggested that the Vav1 CH domain can bind 
to the C1 region, occluding the DH domain and blocking access to GTPases. CH–C1 
interaction apparently stabilizes the inhibitory Tyr174–DH interaction. In addition, the PH 
domain regulates Vav1 catalytic activity by interaction with two inositol lipids: 
phosphatidylinositol 4, 5- bisphosphate (PIP2) and phosphatidylinositol 3, 4, 5-trisphosphate 
(PIP3). Whereas the binding of PIP3 moderately enhances the in vitro GEF activity of Vav1, 
binding to PIP2 has an inhibitory effect. Consistent with this model, Vav1 carrying a single 
mutation in its PH domain is constitutively active and induces cytoskeleton rearrangements 
as a consequence of Rac activation. Deletions of C1 domain or mutations that disrupt its 
structural integrity inhibit Vav1 GEF activity. High resolution X-ray structure of DH–PH–C1 
domains suggests that PH and C1 domains contribute to GEF activity by stabilizing the DH 
domain structure and not through direct contacts with GTPases (Bustelo, 2002).  
GEF activity of Vav1 has long been regarded as the key for transferring the signal from 
activated receptors to the cytoskeleton. Among the molecules constituting the cytoskeleton 
architecture, actin seems to be a preferred target of the Vav1-dependent GEF activity.  
Several partners are involved in the pathway by which Vav1 affects actin cytoskeleton. It 
has been reported that Vav1 is a preferential exchange factor for Rac1, which in turn may 
activate phosphatidylinositol-4-phosphate (PIP) 5-kinase which phosphorylates PIP to PIP2. 
PIP2 may function as an activator of actin-binding proteins, like talin and vinculin, that 
attach the cytoskeleton to the cell membrane. Another potential target for the GEF activity of 
Vav1, Cdc42, may activate the WASP protein, a key mediator of actin polymerization 
(Hornstein et al., 2004). Finally, Vav1-activated small G proteins play an essential role in 
regulating actin cytoskeleton dynamics by also interacting with the p21-activated serine-
threonine kinase (PAK) family of actin-regulatory enzymes (Daniels & Bokoch, 1999). 
In both lymphoid and myeloid cells, like other proteins with a GEF activity, Vav1 mediates a 
number of cytoskeletal-associated cellular processes, being an essential part of the molecular 
link connecting activated receptors to the actin cytoskeleton. A consistent number of studies 
(reviewed in Hornstein et al., 2004) have reported the role of Vav1 in the formation of 
immunological synapse and in phagocytosis of T cells. In non adherent neutrophils, 
stimulation of chemoattractant receptors induces a complex sequence of events: actin 
reorganization, shape changes, development of polarity and reversible adhesion, all 
culminating in chemotaxis. The complex signaling mechanisms that regulate neutrophil 
migration are well studied, and Vav1 appears to be a major point of the inhibitory crosstalk 
between adhesion receptors and cytokine receptors (Gakidis et al., 2004). In particular, the 
activity of Vav1 as GEF for Rac2 is inhibited in adherent cells, as a possible consequence of 
the activation by adhesion of one or more tyrosine phosphatases responsible of 
dephosphorylating Vav1. On the other hand, experiments performed with Vav1-/- mice 
have demonstrated that motility and mobilization into peripheral blood induced in 
neutrophils by FMLP are significantly reduced, as well as the generation of filamentous 
actin (Kim et al., 2003). Studies performed in a rat model have demonstrated that the M-
CSF-induced chemotaxis of bone marrow macrophages is initiated by the 3-
phosphoinositide-dependent GEF activity of Vav1 on Rac (Vedham et al., 2005). 
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In APL-derived HL-60 cells, ATRA treatment induces an increase of total GEF activity, not 
attributable to Vav1, as  deduced by in vitro assays on Ras/Rac small G proteins performed 
on Vav1 immunoprecipitated from both whole cells and isolated nuclei (Bertagnolo et al., 
2001). This implies that, in this cell model, the Syk-dependent tyrosine phosphorylation of 
Vav1 is not ended to regulate its GEF activity and that alternative pathways have to be 
considered to explain the mechanism by which Vav1 affects the organization of cytoskeleton 
and nucleoskeleton during  maturation of tumoral promyelocytes. 
2.2 GEF-independent activity of phosphorylated Vav1  
2.2.1 Regulation of actin cytoskeleton  
In addition to act as a GEF, Vav1 may mediate actin reorganization through other, GEF-
independent mechanisms. The presence in its structure of a number of tyrosines and 
domains potentially involved in protein-protein interactions suggests for Vav1 a role in 
actin polymerization as an adapter protein that links signaling and cytoskeletal molecules. 
In T cells, Vav1 binds constitutively Talin and Vinculin, anchoring the actin cytoskeleton to 
the plasma membrane, and the cytoskeletal protein Zyxin (Hornstein et al., 2004). In the 
same cell model, a direct link between Vav1 and dynamin 2 (Dyn2), a component of the 
cytoskeletal regulators, has also been demonstrated (Gomez et al., 2005).  
A mechanism by means of which tyrosine-phosphorylated Vav1 regulates cytoskeleton of 
ATRA-treated tumoral promyelocytes, identified in HL-60 cells, implies the interaction of 
Vav1 with the p85 regulatory subunit of PI3K. Studies aimed to establish the functional 
meaning of this interaction have demonstrated that, in maturating myeloid precursors, PI3K 
activity closely depends on its association with tyrosine phosphorylated Vav1 and that 
when Vav1/PI3K interaction and/or PI3K activity are abrogated, the phenotypic 
differentiation of ATRA-treated HL-60 is compromised (Bertagnolo et al., 1999, 2004). These 
evidence assign to Vav1/PI3K interaction a prominent function in the regulation of 
cytoskeleton alternative to the described role of 3-phosphoinositides on GEF activity of Vav1 
(Han et al., 1998). 
Also actin participates in the ATRA-induced protein complexes containing Vav1 and PI3K 
in HL-60 cells. Remarkably, when the association between Vav1 and PI3K is inhibited, the 
formation of PI3K/actin complexes is reduced, suggesting that the interaction of PI3K with 
Vav1 is essential for its association with actin (Bertagnolo et al., 2004). Since the recovery of 
3-phosphoinositides is strongly reduced when the Vav1-dependent PI3K/actin interaction is 
abrogated, it can be concluded that Vav1 regulates the physical contact of PI3K with their 
cytoskeleton-associated substrates. These observations suggest that in addition to playing a 
regulatory role in Vav1 activation, PI3K activity may itself be regulated by Vav1.  
PI3K is likely to play essential roles in granulocytic differentiation of tumoral myeloid 
precursors, considering that both down-modulation of its expression and pharmacological 
inhibition of its activity during ATRA treatment significantly reduce the tendency of HL-60 
cells to acquire the differentiated phenotype (Bertagnolo et al., 1999). The response to ATRA 
and the downstream effects of PI3K observed during the induced differentiation support the 
notion that PI3K is recruited in the path controling cytoskeleton in mature granulocytes. In 
fact, PI3K is activated in response to chemotactic factors in murine and human neutrophils 
(Cicchetti et al., 2002; Niggli & Keller, 1997; Stephens et al., 2002) in which newly produced 
PIP3 is involved in determining the localization and possibly the crosslinking/stabilization of 
actin filaments (Chen et al., 2003; Hannigan et al., 2002; Wang et al., 2002). In vitro experiments 
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have demonstrated that PI3K may affect actin-related modifications of cytoskeleton also by 
directly affecting PAK kinase activity (Menard & Mattingly, 2004). PI3K has a more general 
influence on cytoskeleton by determining the amount of the inositol-containing lipids, that 
have  emerged as major players in regulating actin assembly at several levels and with 
different mechanisms, including the direct interaction with cytoskeletal proteins, such as 
vinculin and gelsolin (Janmey et al., 1999, Takenawa & Itoh, 2001). 
 
 
Fig. 1. Schematic representation of the recruitment and phosphorylation of Vav1 in ATRA-
treated promyelocytes. 
Since, in ATRA-treated promyelocytes, both PI3K activity and the modifications of the 
nucleus architecture depend on the formation of Vav1/PI3K complexes, Vav1 may be 
important for targeting PI3K to its nuclear substrates. The association of Vav1 with other 
lipid modifying enzymes, including specific PI-PLC isoforms (Bertagnolo et al., 1998;), 
suggests a more general role of Vav1 in determining the composition of the actin-associated 
phosphoinositide pool and, ultimately, in regulating actin polymerization in differentiating 
HL-60 cells. 
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2.2.2 Regulation of gene expression  
Microarray analysis performed on APL-derived cell lines has identified several genes whose 
expression is modified by ATRA treatment, including genes for a  number of cytokines, in 
turn involved in the differentiative program of tumoral promyelocytes (Hsu et al., 1999; 
Visani et al., 1996). As a consequence of ATRA administration, tyrosine-phosphorylated 
Vav1 accumulates inside the nuclear compartment of APL-derived cells and becomes 
involved in the changes of nuclear morphology. Since local reorganization of nuclear 
architecture is required for both transcription and post-transcriptional events, it is 
conceivable that Vav1 plays a role in regulating ATRA-related gene expression.  
An array analysis performed on HL-60 cells focussed on genes coding for cytokines and 
cytokine receptors indicates that the inhibition of the Syk-dependent tyrosine-
phosphorylation of Vav1 during ATRA treatment prevents the ATRA-induced expression of 
8 genes (Bertagnolo et al., 2005). Among them, the thymosin beta-10 (TMSB10) gene has 
been found, encoding for a small G-actin binding protein that induces depolymerization of 
intracellular F-actin pools and thus deeply affects actin architecture (Liu et al., 2004; Rho et 
al., 2004). Tyrosine-phosphorylated Vav1 is also involved in regulating the ATRA-induced 
expression of the gene for Notch homolog, that codifies for a molecule playing a role in 
mediating cell fate decisions during hematopoiesis (Ohishi et al., 2003) and whose signaling 
might be necessary for the proliferation and survival of AML cells, possibly through the 
maintenance of the expression of c-Myc and Bcl2, as well as the phosphorylation of the Rb 
protein (Li et al., 2010). The involvement of Vav1 in regulating ATRA-dependent expression 
of cytokines and/or growth factors has been ascertained by silencing Vav1 during ATRA 
admistration, further confirming that the increase of Vav1 expression is not an 
epiphenomenon but constitutes a key event able to actually promote the granulocytic 
maturation of tumoral myeloid precursors. 
The evidence that Vav1 has a role in regulating ATRA-dependent gene expression in APL-
derived cells suggests the participation of Vav1 to transcriptional complexes activated by 
ATRA, also considering that, in both myeloid and lymphoid cells, Vav1 seems to be 
involved in regulating DNA transcription, by direct interaction with, or as a facilitator of, 
transcription factors (Katzav, 2004). In particular, Vav1 regulates Nuclear Factor of 
Activated T-cells (NFAT), Activator Protein-1 (AP-1) and Nuclear Factor κB (NF-κB) in T-
cells in response to TCR stimulation, and exerts a specific role in regulating the CREB-
dependent gene transcription (Haubert & Weckbecker, 2010; Schneider & Rudd, 2008).  
Direct evidence for the presence of Vav1 as a component of an active transcriptional 
complex has been reported by Houlard et al. (2002) demonstrating the participation of Vav1 
in complexes with NFAT and NF-kB-like, as facilitator of their transcriptional activity. 
In APL-derived cells, nuclear Vav1 associates with PU.1 (Brugnoli et al., 2010), a 
transcription factor induced by ATRA and able to play a crucial role in the completion of 
granulocytic differentiation of APL-derived myeloid precursors (Mueller et al., 2006). In 
particular, the down-modulation of PU.1 by means of specific siRNAs has allowed to 
establish that, like in other tumoral myeloid precursors (Denkinger et al., 2002), PU.1 
regulates the expression of Vav1 induced by ATRA in NB4 cells (Brugnoli et al., 2010).  
In AML-derived myeloid precursors, PU.l represents a major determinant of the myeloid 
expression of CD11b (Kastner & Chan, 2008; Pahl et al., 1993), an integrin receptor whose 
surface expression increases concurrently with CD11b mRNA levels during myeloid 
differentiation of APL-derived cell lines (Barber et al., 2008). Chromatin 
immunoprecipitation (ChIP) experiments performed on NB4 cells treated with ATRA have 
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demonstrated that PU.1 is recruited to its consensus sequence within the CD11b promoter 
(Brugnoli et al., 2010). Since the over-expression of PU.1 might influence phenotype and 
restore differentiation of primary myeloid leukemic blasts (Durual et al., 2007), and its 
silencing counteracts the ATRA ability to induce the expression of the granulocytic marker 
CD11b (Mueller et al., 2006), PU.1 may be used by ATRA to promote CD11b expression 
during the late stages of the maturation of APL-derived cells. This is confirmed by in vitro 
experiments demonstrating the formation of PU.1-containing complexes on the CD11b 
promoter (Brugnoli et al., 2010). 
 
 
Fig. 2. Schematic representation of the involvement of Vav1 in regulating gene expression in 
differentiating promyelocytes. 
Also Vav1 is recruited to the PU.1 consensus sequence on the CD11b promoter in untreated 
NB4 cells. ATRA treatment, by inducing an increase in Syk-dependent tyrosine 
phosphorylation of Vav1, displaces this protein from existing molecular complexes on the 
CD11b promoter. Accordingly, the specific inhibition of Syk activity is accompanied by the 
appearance of a Vav1-containing complex (Brugnoli et al., 2010). The participation of Vav1 
to molecular complexes including PU.1 has been ruled out by EMSA experiments. On the 
other hand, both expression and tyrosine phosphorylation levels of Vav1 seem to play a role 
in regulating the formation of PU.1-containing complexes. In fact, when the amount of Vav1 
is forcedly reduced or its tyrosine phosphorylation is inhibited during the differentiation 
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2010). It is then conceivable that Vav1, and in particular tyrosine-phosphorylated Vav1, 
regulates the recruitment of PU.1 to its consensus sequence on the CD11b promoter region 
and, possibly, the expression of this surface antigen. 
3. Vav1 and protein expression  
Proteome analysis currently provides the opportunity to identify global changes in gene 
expression by directly measuring protein amount. A number of recent studies have used 
this approach to evaluate protein expression during differentiation/apoptosis induced by 
different agonists in APL-derived cells. In particular, it has been reported that ATRA 
modulates the expression level of structural and signal transduction proteins as well as of 
molecules involved in the different phases of protein synthesis (Dong et al, 2006; Harris et 
al., 2004; Wan et al., 2001; Wang et al., 2004;).  
On the basis of the evidence that inside the nucleus of a number of different cell lines, 
including APL-derived cells, Vav1 participates to molecular complexes with DNA-related 
proteins (Brugnoli et al., 2010; Houlard et al., 2002; Romero et al., 1998) a more general role 
of Vav1 in regulating events ended to control protein expression can be hypothesized. 2D 
electrophoresis followed by mass spectrometry have established that, in both HL-60 and 
NB4 cells, the down-modulation of Vav1 abrogates the capacity of ATRA of modulating the 
expression of proteins associated to cytoskeleton and involved in proliferation and of 
apoptosis-related proteins, as well as of molecules implicated in metabolism, synthesis, 
folding and degradation of proteins (Bertagnolo et al., 2008). The majority of the identified 
proteins are affected by Vav1 down-modulation only in one of the two analyzed cell lines, 
according to the notion that HL-60 and NB4 cells, even if both derived from patients with 
APL, show peculiar genotypic and phenotypic profiles (Barber et al., 2008). Interestingly, in 
NB4 cells, the lack of Vav1 affects the ATRA-dependent expression of the Splicing factor, 
arg/ser rich 3 (Sfrs3), a member of SR proteins, known as non-snRNP splicing factors, that 
may affect both constitutive and alternative splicing of mRNA (Sanford et al., 2005). This 
evidence further supports the role of Vav1 in regulating the ATRA-dependent gene 
expression.   
Some of the identified proteins are differentially expressed, as a consequence of Vav1-down-
modulation during ATRA treatment, in both cell lines, suggesting that they may constitute a 
common part of the signalling activated by ATRA in APL-derived promyelocytes. Notably, 
this group of proteins includes the  isoform of the 14-3-3 family of proteins, specifically 
involved in the caspase networks (Liou et al., 2007). The increased expression of 14-3-3 in 
both HL-60 and NB4 cells when Vav1 is down-modulated during ATRA treatment suggests 
that the amount of Vav1 may be critical in determining the mechanism of caspase activation 
in APL.  
Vav1 also affects the ATRA-dependent expression of -enolase, a multifunction protein 
involved in glycolysis and up-regulated in the sera of a number of cancer patients, in which 
it seems to have a role in tumorigenesis (Zou et al., 2005). -enolase is expressed at high 
levels in most AML subtypes in which it might contribute to the adverse evolution of the 
disease (Lopez-Pedrera et al., 2006). Since down-modulation of Vav1 during ATRA 
treatment of APL-derived cells reduces the expression of -enolase (Bertagnolo et al., 2008), 
it has been suggested that Vav1 promotes the differentiation of tumoral promyelocytes by 
also targeting metabolic pathways.  
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The proteasome component “splice isoform 2 subunit 3” is down-modulated as well in 
HL-60 and NB4 cells under the same experimental conditions (Bertagnolo et al., 2008). Since 
proteasome is the major cellular proteolytic machinery responsible for degradation of 
normal and damaged proteins (Von Mikecz, 2006), Vav1 may also be involved in regulating 
protein degradation during ATRA dependent maturation of tumoral promyelocytes. 
Also the component of microtubules -tubulin is affected by down-modulation of Vav1 
during ATRA treatment (Bertagnolo et al., 2008), indicating that Vav1, in addition to 
regulate cytoskeleton reorganization, takes part to the profound architectural changes of 
differentiating promyelocytes by regulating the expression of cytoskeleton components.  
4. Vav1 and monocytic/macrophagic differentiation 
The human promyelocytic leukemia cell lines HL-60 and NB4 can be differentiated either 
toward neutrophils by ATRA or to monocytes/macrophages by PMA (Murao et al., 1983; 
Song & Norman, 1998). PMA is a stable analogue of 2, 3-diacylglycerol that induces, even if 
with dynamics not identical in HL-60 and NB4 cells, morphological and functional changes 
related to monocyte maturation, accompanied by a loss of proliferative capacity (Jasek et al., 
2008). Immunochemical and immunocytochemical analysis demonstrate that the expression 
of Vav1 increases also during the PMA-induced acquisition of a monocyte-like phenotype of 
HL-60 and NB4 cells (Bertagnolo et al., 2011). This is consistent with the notion that also 
mature monocytes express Vav1 and that proper amounts of the protein are necessary for 
their inflammation related functions (Bhavsar et al., 2009; Hall et al., 2006). In the same cell 
types, PMA also induces a relevant increase of tyrosine phosphorylation of Vav1. On the 
other hand, and in constrast to what observed in the ATRA-treatment of the same cell line, 
no role for Syk was demonstrated in this event (Bertagnolo et al., 2011), consistent with the 
notion that, at least in HL-60 cells, Syk might exert a narrower role, restricted to directing 
cells toward granulocyte differentiation (Qin & Yamamura, 1997). In both HL-60 and NB4 
cells, PMA induces a relevant increase of tyrosine phosphorylation of Vav1 on the Tyr174 
residue (Bertagnolo et al., 2011), according to the GEF role played by Vav1 in myeloid cells. 
These results are also in agreement with other data indicating that, in macrophage-like 
differentiated HL-60 cells, the activity of Syk is ended to regulate the roles played by mature 
cells in immune response, including their complement-mediated phagocytosis, in which the 
kinase regulates both actin dynamics and the Vav1-RhoA activation pathway (Shi et al., 
2006). 
Also in differentiation of APL-derived cells to monocytes/macrophages, a crucial role for 
Vav1 in determining the acquisition of maturation-related features has been demonstrated 
by silencing the expression of Vav1 induced by PMA (Bertagnolo et al., 2011). Under these 
conditions, the expression of CD11b, which is induced by PMA and constitutes a marker 
also for monocyte differentiation, is significantly reduced, similarly to what demonstrated 
during the treatment with ATRA of HL-60 and NB4 cells (Bertagnolo et al. 2011). This 
suggests that, in differentiating APL-derived cells, Vav1 plays a role in regulating the 
expression of the CD11b surface antigen regardless the agonist employed and the 
maturation lineage. Since in NB4 cells treated with ATRA Vav1 is recuited to protein/DNA 
complexes on the CD11b promoter (Brugnoli et al., 2010), it can be speculated that Vav1 
plays a specific role in driving the expression of CD11b as part of the transcriptional 
machinery also during the differentiation of NB4 cells along the monocytic/macrophagic 
lineage. 
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Also cell adhesion is affected by down-modulation of Vav1 during PMA treatment of HL-60 
and NB4 cells, in terms of both number of adherent cells and of adhesion area of cells that 
remain attached to the flask bottom. These results are in agreement with the data obtained 
with macrophages from Vav1_/_ mice, showing a smaller adhesive area or a decreased 
adhesion efficiency (Wells et al., 2005).  
4.1 Regulation of actin  
As above reported, the main known functional role of tyrosine phosphorylated Vav1 is to 
regulate cytoskeleton reorganization, a phenomenon at the basis of both adhesion and 
migration of monocytes/macrophages. Vav1 regulates cell architecture not only by means of 
its GEF activity but also by interacting with proteins in turn involved in cytoskeleton 
reorganization. In addition, in both HL-60 and NB4 cells, Vav1 affects the ATRA-induced 
expression of the microtubule component -tubulin.  
Contrarily to what observed during granulocytic differentiation, Vav1 down-modulation 
does not have any effect on expression and architectural organization of -tubulin during 
PMA-induced monocytic/macrophagic maturation of NB4 cells (Bertagnolo et al., 2011). 
This indicates that, during the maturation process of APL-derived cells, Vav1 exerts an 
agonist- and lineage-specific role in regulating -tubulin. From a more general point of 
view, concerning microtubule organization, it can be speculated that the role of Vav1 is 
restricted to the control of the motility of mature cells, as also suggested by the evidence that 
changes in microtubule dynamics contribute to the reduced migration speed of Vav1_/_ 
macrophages in response to CSF-1 (Wells et al., 2005). 
In living cells, the F-actin cytoskeleton encompasses a variety of different structures that are 
essential for many different aspects of cell physiology. In particular, dynamic modulation of 
the filamentous actin cytoskeleton is critical to numerous physical cellular processes, 
including adhesion, migration and phagocytosis, all requiring precise regulation of cell 
shape  (Stricker et al., 2010). Recent data demonstrate that Vav proteins, including Vav1, are 
required for actin cytoskeleton reorganization during migration of macrophages, by 
coupling RhoA and Rac1 activity to adhesion receptors (Bhavsar et al., 2009). Also in ATRA-
induced maturation of cells derived from APL Vav1 seems to regulate actin organization.  
In HL-60 and NB4 cells treated with PMA, an unprecedented involvement of Vav1 in 
regulating the increase of actin expression has been shown very recently (Bertagnolo et al., 
2011), that constitutes a further confirmation that Vav1, besides being involved in the 
formation of filaments, takes part to cytoskeleton reorganization as a modulator of protein 
expression. 
The modifications of cell shape in the different cell processes seem to be regulated by the 
existence of the F-actin cortex, a thin, membrane-bound F-actin network (Stricker et al., 
2010). Defective actin-cap formation has been found in lymphocytes from a Vav-deficient 
mice, clearly correlating Vav1 activity with the regulation of cell shape (Holsinger et al., 
1998). Furthermore, a recent work in which adhesive micropatterned surfaces have been 
used to control the overall shape of fibroblasts, has demonstrated that the shape of the 
nucleus is tightly regulated through a perinuclear actin cap, which is located above and 
around the interphase nucleus (Khatau et al., 2009). A wide variety of contractile F-actin 
networks with different architectures and polarity have also been found near cell adhesion 
surfaces, correlated with the migratory capability of adherent cells (Stricker et al., 2010). By 
means of confocal analysis of PMA-treated adherent NB4 cells, it has been demonstrated the 
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existence of an agonist-induced F-actin network, in which F-actin colocalyzes with Vav1, 
that sharply defines the cytoplasmatic cell border, accumulates inside thin and long cell 
processes and surrounds the nuclear compartment (Bertagnolo et al., 2011). Since the 
existence of cytoplasmatic processes in PMA-treated adherent cells are indicative of 
migratory activity (Stricker et al., 2010), Vav1/F-actin co-localization in cytoplasm 
protrusions is suggestive of a synergy of the two molecules in controling cell motility. This 
is in agreement with the role described for Vav proteins in the maintenance of normal 
morphology and migratory behaviour in macrophages (Bhavsar et al., 2009). The strong  
Vav1/F-actin co-localization observed at the nuclear periphery and, in particular, in the 
region above the nucleus, suggests that the two proteins may cooperate in regulating the 
shape of the nucleus through an actin filament structure similar to the perinuclear actin cap 
described by Khatau et al. (2009). On the other hand, the role of Vav1 in modulating cell 
adhesion of PMA-treated cells seems to be related to its ability to regulate expression of 
integrins, like CD11b, rather than to a direct effect on actin-based cytoskeleton. 
5. Conclusion 
The present review focuses on the role of the multidomain protein Vav1 in promoting and 
sustaining the completion of the differentiation program of tumoral promyelocytes. Vav1 is 
a key protein in the ATRA- and PMA-induced maturation of APL-derived cells, since either 
its down-modulation or over-expression respectively prevents or potentiates the ability of 
these agonists to induce the acquisition of a mature phenotype. Alternatively to the best 
known function of Vav1 as a GEF for small G proteins, ended to regulate cell shape by 
affecting actin assembly, other mechanisms by which Vav1 affects myeloid differentiation 
have been described, reflecting the great interactive and regulatory potential of Vav1, which 
make the full understanding of its functions a very difficult, yet fascinating story.   
An example of the complex role played by Vav1 during myeloid differentiation of APL-
derived cells is the interaction of Vav1 with various lipid-modifying enzymes ended to 
regulate the pool of phosphoinositides associated to cytoskeleton. The resulting 
modifications of actin cytoskeleton contribute to the changes of cellular and nuclear shape 
occurring in differentiating tumoral promyelocytes (Fig. 3).  
The participation of Vav1 to molecular complexes with other adaptor proteins differently 
distributed in the cytoplasm and in the nucleus suggests the existence of a signal sequence 
originated from membrane receptors and directed to the nuclear compartment. Inside the 
nucleus of APL-derived cells, Vav1 seems to play its most intriguing role by regulating the 
expression of CD11b, a surface marker of both granulocyte and monocyte differentiation, 
and of a number of ATRA-modulated proteins (Fig. 3). The nuclear issue assumes thus great 
relevance, confering to Vav1 compartimentalized strategic roles in regulating the maturation 
process of tumoral promyelocytes. 
The bulk of the studies reviewed here are mostly concerned with two cell lines, HL-60 and 
NB4, derived from APL patients, driven to achieve differentiation by treatment with drugs 
of the retinoids or phorbol esters families. Even though a better understanding of the 
functional engagement of Vav1 will be required before converting scientific achievements 
into clinical advances, Vav1 might be considered a common target for developing new 
therapeutic strategies for the different subtypes of myeloid leukemias.  
In addition, it can be speculated that the identified pathways involving Vav1 are of more 
general interest and may be potentially extended also outside the 
haemopoietic/immunological systems. 
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Fig. 3. Overall role of Vav1 in regulating maturation of APL-derived promyelocytes. 
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